Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03293641
Other study ID # KEMRI SSC 2925
Secondary ID
Status Completed
Phase N/A
First received April 14, 2017
Last updated September 25, 2017
Start date May 20, 2016
Est. completion date January 19, 2017

Study information

Verified date September 2017
Source Kenya Medical Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Zinc is a nutritionally essential trace element found in previous studies to reduce growth retardation and improve immune function, which may also result in decreased incidence of infectious diseases including malaria, pneumonia and diarrhea. Sickle Cell Disease (SCD) patients are known to be susceptible to zinc deficiency and appear to benefit from zinc supplementation. The proposed pilot research project aims to investigate the influence of zinc supplementation on incidence of malaria infections, incidence of bacterial infections and investigate the influence of zinc supplementation on morbidity in children with SCD in western Kenya. The differences in incidence of morbidity and other secondary endpoints will be compared between the zinc group and the control group.


Description:

Zinc is a nutritionally essential trace element found in previous studies to reduce growth retardation and improve immune function, which may also result in decreased incidence of infectious diseases including malaria, pneumonia and diarrhea. SCD patients are known to be susceptible to zinc deficiency and appear to benefit from zinc supplementation. Despite these findings, SCD patients in Kenya have not benefited from zinc supplementation programs due to a lack of research and findings to inform policy in the East African-setting. The proposed pilot research project aims to investigate the influence of zinc supplementation on incidence of malaria infections in children with SCD; investigate the influence of zinc supplementation on incidence of bacterial infections (e.g. S pneumoniae, H influenzae and non-typhi Salmonella species) in children with SCD and investigate the influence of zinc supplementation on morbidity in children with SCD in western Kenya. A 6 month randomized controlled pilot trial involving children with SCD aged 6 months to less than 13 years, being treated and followed up routinely at the KEMRI-site and other selected health facilities in Western Kenya for SCD will be enrolled. The children will be randomized into two arms, with the Intervention Group receiving the recommended Ministry of Health (MoH)/World Health Organization (WHO) standard care in addition to three times weekly zinc supplementation (10 mg) and the Control Group receiving standard MoH care alone over a six month period. At baseline, at 3 months and at 6 months, clinical and laboratory evaluations, including serum zinc levels, malaria blood slides, anthropometric measurements and other indicated laboratory tests will be conducted.The differences in incidence of morbidity and other secondary endpoints will be compared between the zinc group and the control group. The results are expected to determine the scientific basis for a larger clinical trial to determine the need for the addition of zinc supplement to the management of sickle cell disease.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date January 19, 2017
Est. primary completion date January 19, 2017
Accepts healthy volunteers No
Gender All
Age group 6 Months to 12 Years
Eligibility Inclusion Criteria:

- Male or female infants and children = 6 months and < 13 years of age with confirmed SCD.

- Written informed consent obtained from the participant's parent/Legally Acceptable Representative (LAR).

- Available to participate for the study duration (approximately six months)

Exclusion Criteria:

- Written informed consent NOT obtained from the participant's parent/Legally Acceptable Representative (LAR).

- Profound clinical evidence of current immunosuppression or evidence of active AIDS defining illness i.e. WHO HIV clinical stage III/IV

- History of allergic reactions to zinc or any other ingredients in the supplement

- History of any neurologic disorders or seizures

- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, renal functional abnormality, as determined by physical examination or laboratory screening tests

- Hemoglobin =7.0 g/dL in children aged 6 months to = 2 years.

- Hemoglobin = 6 g/dL in children aged >2yrs to <13 years.

- Total White Cell Count below normal range <4.5 x 103/uL

- Use of any investigational or non-registered drugs or vaccines or planned use

- Simultaneous participation in any other clinical trial

- Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.

Study Design


Intervention

Dietary Supplement:
Zinc Sulfate Tablets
Zinc Sulfate Tablets 3 times every 7 days for 6 months.
Drug:
Standard of Care
Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Lucas Otieno Tina, MD MSc GlaxoSmithKline, Strathmore University

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of change in zinc levels from baseline at study conclusion. Zinc Levels in Plasma 6 months
Secondary Number of malaria episodes among recipients of zinc versus controls diagnosed by RDT or Microscopy. Malaria Incidence 6 months
Secondary Number of episodes of bacterial infections among recipients of zinc versus controls diagnosed by culture. Bacterial Infection Incidence 6 months
Secondary Incidence of malnutrition among recipients of zinc versus controls diagnosed based on anthropometric measurements. Anthropometric Measurements i.e. Weight, Height and Mid Upper Arm Circumference 6 months
Secondary Occurrences of Adverse Events (AEs) during the 6 month follow-up period among recipients of zinc versus controls. Adverse Events including Serious Adverse Events 6 months
See also
  Status Clinical Trial Phase
Completed NCT02227472 - Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
Recruiting NCT06301893 - Uganda Sickle Surveillance Study (US-3)
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT02522104 - Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Phase 4
Recruiting NCT04688411 - An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease N/A
Terminated NCT03615924 - Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease Phase 3
Not yet recruiting NCT06300723 - Clinical Study of BRL-101 in Severe SCD N/A
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Completed NCT04134299 - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease N/A
Completed NCT04917783 - Health Literacy - Neurocognitive Screening in Pediatric SCD N/A
Completed NCT02580565 - Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04388241 - Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD N/A
Recruiting NCT05431088 - A Phase 2/3 Study in Adult and Pediatric Participants With SCD Phase 2/Phase 3
Completed NCT01158794 - Genes Influencing Iron Overload State
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Withdrawn NCT02960503 - Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease Phase 1/Phase 2
Completed NCT02565082 - Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients N/A
Withdrawn NCT02630394 - A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease Phase 1
Completed NCT02567695 - A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects Phase 1